PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response

Theranostics are emerging as a pillar of cancer therapy that enable the use of single molecule constructs for diagnostic and therapeutic application. As poly adenosine diphosphate (ADP)-ribose polymerase 1 (PARP-1) is overexpressed in various cancer types, and is localized to the nucleus, PARP-1 can...

Full description

Bibliographic Details
Main Authors: Aladdin Riad, Sarah B. Gitto, Hwan Lee, Harrison D. Winters, Paul M. Martorano, Chia-Ju Hsieh, Kuiying Xu, Dalia K. Omran, Daniel J. Powell, Robert H. Mach, Mehran Makvandi
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Molecules
Subjects:
Auger therapy
radiopharmaceutical therapy
theranostic
PARP-1
ovarian cancer
BRCA1
Online Access:https://www.mdpi.com/1420-3049/25/24/6029

Internet

https://www.mdpi.com/1420-3049/25/24/6029

Similar Items